One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Using Molecular Stratification for Smart Combination Therapies.
Hont, Amy B. MD 1,; Bollard, Catherine M. MD 1,
doi : 10.1200/JCO.21.01804
Volume 39(32) pgs. 3527-3650 November 10, 2021
Testicular Cancer Survivorship: Looking Back to Move Forward.
Fung, Chunkit MD, MSCE 1,; Travis, Lois B. MD, ScD 2,
doi : 10.1200/JCO.21.01984
Should Everyone With Ductal Carcinoma in Situ Receive Adjuvant Radiation?.
Warren, Laura E. G. MD 1; Bellon, Jennifer R. MD 1,,
doi : 10.1200/JCO.21.01896
Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?.
Tarantino, Paolo MD 1,2; Tolaney, Sara M. MD, PhD 3,4,; Harbeck, Nadia MD, PhD 5,; Cortes, Javier MD, PhD 6,7,; Curigliano, Giuseppe MD, PhD 1,2,,
doi : 10.1200/JCO.21.01059
Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSe-ESMART Trial.
Bautista, Francisco MD, PhD 1; Paoletti, Xavier PhD 2,3,; Rubino, Jonathan MSc 4,; Brard, Caroline PhD 2; Rezai, Keyvan PhD 5; Nebchi, Souad MChem 2; Andre, Nicolas MD, PhD 6,7,; Aerts, Isabelle MD 8,; De Carli, Emilie MD 9; van Eijkelenburg, Natasha MD 10; Thebaud, Estelle MD 11; Corradini, Nadege MD 12; Defachelles, Anne-Sophie MD 13; Ducassou, Stephane MD, PhD 14; Morscher, Raphael J. MD, PhD 15,16; Vassal, Gilles MD, PhD 4,; Geoerger, Birgit MD, PhD 15,16,,
doi : 10.1200/JCO.21.01152
Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort.
Hellesnes, Ragnhild MD 1,2,; Myklebust, Tor Age PhD 3,4; Fossa, Sophie D. MD, PhD 4,5,6; Bremnes, Roy M. MD, PhD 1,2; Karlsdottir, Asa MD, PhD 7; Kvammen, Oivind MD, PhD 8; Tandstad, Torgrim MD, PhD 9,10; Wilsgaard, Tom PhD 11; Negaard, Helene F. S. MD, PhD 5; Haugnes, Hege S. MD, PhD 1,2
doi : 10.1200/JCO.21.00637
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.
McCormick, Beryl MD 1,,; Winter, Kathryn A. MS 2; Woodward, Wendy MD, PhD 3; Kuerer, Henry M. MD 3,; Sneige, Nour MD 3; Rakovitch, Eileen MD 4,; Smith, Barbara L. MD 5,; Germain, Isabelle MD 6; Hartford, Alan C. MD 7; O'Rourke, Mark A. MD 8; Walker, Eleanor M. MD 9; Strom, Eric A. MD 3; Hopkins, Judith O. MD 10,; Pierce, Lori J. MD 11,; Pu, Anthony T. MD 12; Sumida, Kenneth N. M. MD 13,; Vesprini, Danny MD 14,; Moughan, Jennifer MS 2; White, Julia R. MD 14,
doi : 10.1200/JCO.21.01083
Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions.
Lansinger, Olivia M. BS 1; Biedermann, Savanna BS 1; He, Zihuai BS 1; Colevas, A. Dimitrios MD 1,,
doi : 10.1200/JCO.21.01200
Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma.
Cutter, David J. MD, DPhil 1,2,; Ramroth, Johanna DPhil 1,; Diez, Patricia MSc 3; Buckle, Andy MSc 2; Ntentas, Georgios DPhil 1,4; Popova, Bilyana MSc 5; Clifton-Hadley, Laura PhD 5,; Hoskin, Peter J. MD 3,6,; Darby, Sarah C. PhD 1; Radford, John MD 6,; Illidge, Tim MD, PhD 6,
doi : 10.1200/JCO.21.00408
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
Bahlis, Nizar J. MD 1,,; Baz, Rachid MD 2,; Harrison, Simon J. MD 3,; Quach, Hang MD 4,; Ho, Shir-Jing MD 5; Vangsted, Annette Juul MD 6; Plesner, Torben MD 7,; Moreau, Philippe MD 8,; Gibbs, Simon D. MD 9,; Coppola, Sheryl PhD 10; Yang, Xiaoqing MHSc 10; Al Masud, Abdullah PhD 10,; Ross, Jeremy A. PhD 10,; Bueno, Orlando MD 10,; Kaufman, Jonathan L. MD 11,
doi : 10.1200/JCO.21.00443
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.
Sonneveld, Pieter MD 1,,; Dimopoulos, Meletios A. MD 2,; Beksac, Meral MD 3,,; van der Holt, Bronno PhD 4; Aquino, Sara MD 5; Ludwig, Heinz MD 6,; Zweegman, Sonja MD 7,; Zander, Thilo MD 8; Zamagni, Elena MD 9,; Wester, Ruth MD 1,; Hajek, Roman MD 10,; Pantani, Lucia MD 11,; Dozza, Luca MSc 12; Gay, Francesca MD 13,; Cafro, AnneMaria MD 14; De Rosa, Luca MD 15; Morelli, Annamaria MD 16; Gregersen, Henrik MD 17; Gulbrandsen, Nina MD 18; Cornelisse, Petra MSc 19; Troia, Rosella PharmD 13; Oliva, Stefania MD 13,; van de Velden, Vincent PhD 20,; Wu, KaLung MD 21,; Ypma, Paula F. MD 22; Bos, Gerard MD 23,; Levin, Mark-David MD 24,; Pour, Luca PhD 25; Driessen, Christoph MD 26; Broijl, Annemiek MD 1,; Croockewit, Alexandra MD 27; Minnema, Monique C. MD 28,; Waage, Anders MD 29,; Hveding, Cecilie MD 30,; van de Donk, Niels W. C. J. MD 7,; Offidani, Massimo MD 31,; Palumbo, Giuseppe A. MD 32,; Spencer, Andrew MD 33,; Boccadoro, Mario MD 13,; Cavo, Michele MD 34,
doi : 10.1200/JCO.21.01045
Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II.
Oonk, Maaike H. M. PhD 1,; Slomovitz, Brian MD 2,; Baldwin, Peter J. W. MD 3; van Doorn, Helena C. PhD 4; van der Velden, Jacobus PhD 5; de Hullu, Joanne A. PhD 6; Gaarenstroom, Katja N. PhD 7; Slangen, Brigitte F. M. PhD 8; Vergote, Ignace MD 9,; Brannstrom, Mats MD 10,; van Dorst, Eleonora B. L. MD 11; van Driel, Willemien J. PhD 12; Hermans, Ralph H. PhD 13; Nunns, David FRCOG 14; Widschwendter, Martin MD 15,; Nugent, David PhD 16; Holland, Cathrine M. PhD 17; Sharma, Aarti PhD 18; DiSilvestro, Paul A. MD 19,; Mannel, Robert MD 20,; Boll, Dorry PhD 13,; Cibula, David MD 21,; Covens, Al MD 22; Provencher, Diane MD 23,; Runnebaum, Ingo B. MD 24,; Luesley, David MD 25; Ellis, Patricia MD 26; Duncan, Timothy J. MD 27; Tjiong, Ming Y. PhD 5; Cruickshank, Derek J. FRCOG 28; Kjolhede, Preben PhD 29,; Levenback, Charles F. MD 30; Bouda, Jiri MD 31; Kieser, Katharina E. MD 32,; Palle, Connie PhD 33; Spirtos, Nicola M. MD 34,; O'Malley, David M. MD 35,; Leitao, Mario M. MD 36,; Geller, Melissa A. MD 37,; Dhar, Kalyan MD 38; Asher, Viren MD 39; Tamussino, Karl MD 40,; Tobias, Daniel H. MD 41,; Borgfeldt, Christer PhD 42; Lea, Jayanthi S. MD 43,; Bailey, Jo MD 44; Lood, Margareta MD 45; Eyjolfsdottir, Brynhildur MD 46,; Attard-Montalto, Stephen MD 47; Tewari, Krishnansu S. MD 48,; Manchanda, Ranjit PhD 49,; Jensen, Pernille T. PhD 50; Persson, Par PhD 51; Van Le, Linda MD 52,; Putter, Hein PhD 7; de Bock, Geertruida H. PhD 1; Monk, Bradley J. MD 53,; Creutzberg, Carien L. PhD 7,; van der Zee, Ate G. J. PhD 1
doi : 10.1200/JCO.21.00006
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
Ramalingam, Suresh S. MD 1,,; Novello, Silvia PhD 2,; Guclu, Salih Zeki PhD 3,4; Bentsion, Dmitry MD 5; Zvirbule, Zanete MD 6; Szilasi, Maria MD, PhD 7; Bernabe, Reyes MD 8; Syrigos, Konstantinos PhD 9,; Byers, Lauren Averett MD 10,; Clingan, Philip MB, BS 11; Bar, Jair MD, PhD 12,; Vokes, Everett E. MD 13,; Govindan, Ramaswamy MD 14,; Dunbar, Martin PhD 15,; Ansell, Peter PhD 15,; He, Lei PhD 15,; Huang, Xin PhD 15,; Sehgal, Vasudha PhD 15; Glasgow, Jaimee PhD 15,; Bach, Bruce A. PhD 15,; Mazieres, Julien PhD 16,
doi : 10.1200/JCO.20.03318
Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Escalation or De-Escalation?.
Tanaka, Maho RPh; Shimomura, Akihiko MD, PhD; Terakado, Hiroyuki RPh; Shimizu, Chikako MD, PhD
doi : 10.1200/JCO.21.01716
Reply to M. Tanaka et al.
Tolaney, Sara M. MD, MPH; Partridge, Ann H. MD, MPH; Winer, Eric P. MD; Krop, Ian E. MD, PhD
doi : 10.1200/JCO.21.01967
